Trials / Completed
CompletedNCT04409262
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia
A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 Pneumonia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 649 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remdesivir | Participants will receive intravenous (IV) RDV |
| DRUG | Tocilizumab | Participants will receive IV TCZ |
| DRUG | Placebo | Participants will receive IV placebo matched to TCZ |
Timeline
- Start date
- 2020-06-16
- Primary completion
- 2021-02-01
- Completion
- 2021-03-08
- First posted
- 2020-06-01
- Last updated
- 2022-02-14
- Results posted
- 2022-02-14
Locations
54 sites across 4 countries: United States, Brazil, Russia, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04409262. Inclusion in this directory is not an endorsement.